XTL Biopharmaceuticals Ltd. XTLB
2.20
(0.21)
(8.71%)
as of 25 Sep
- Market cap
- $9.7M
- P/E
- 0.0×
Follow XTLB
| Jun '25 | Sep '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | (34.60%) | 0.00% |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | (32.03%) | 0.00% | ||
ROIC |
0.00% | 0.00% | (149.76%) | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | (43.06%) | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
— | — | 0.00 | — | |
Free Cash Flow |
— | — | — | — | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | 0.00 | — | |
Research and Development Expense of Revenue |
— | — | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | — | |
Interest Coverage |
— | — | 0.00 | — | |
Operating CF/Net income |
— | — | 0.00 | — | |
Depreciation/Fixed assets |
0.00 | 0.00 | — | — | |
Revenue per Share |
— | — | 0.00 | — | |
Operating CF per Share |
— | — | 0.00 | — | |
Capex per Share |
— | — | 0.00 | — | |
Net Profit Margin |
— | — | 0.00% | — |
Columns are period end dates